cmAngio® vs CARTO 3 EP Navigation System Software V8.0 (FG-5400-00

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

cmAngio®

by CureMetrix

CARTO 3 EP Navigation System Software V8.0 (FG-5400-00

by Biosense Webster, Inc.

AI Verdict

Tool A is designed for early cardiovascular risk assessment by detecting breast arterial calcifications on mammograms, primarily benefiting radiologists and OB/GYNs. Tool B, conversely, is an advanced 3D cardiac mapping and navigation system for electrophysiologists, focused on diagnosing and treating existing heart rhythm disorders. While both leverage AI in cardiology, their distinct applications in risk assessment versus interventional treatment make them suitable for different clinical needs.

Choose cmAngio® if…

Choose cmAngio® if your primary goal is to leverage existing mammography data for early, non-invasive cardiovascular risk assessment in women. This tool is ideal for identifying Breast Arterial Calcifications (BAC) to provide insights into potential cardiovascular health concerns without additional radiation or procedures, aiding in proactive patient management and population health initiatives.

View cmAngio® →

Choose CARTO 3 EP Navigation System Software V8.0 (FG-5400-00 if…

Choose CARTO™ 3 EP Navigation System Software V8.0 if you are an electrophysiologist requiring advanced, real-time 3D cardiac mapping and navigation for diagnosing and treating complex heart rhythm disorders. This system is best suited for interventional procedures, offering precise catheter visualization, rapid anatomical mapping, and enhanced signal analysis to optimize ablation strategies for conditions like AFib and VT.

View CARTO 3 EP Navigation System Software V8.0 (FG-5400-00 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	cmAngio®	CARTO 3 EP Navigation System Software V8.0 (FG-5400-00
Pricing	Paid, out-of-pocket	Unknown
Deployment	Cloud-based, integrates with any DICOM-compliant viewer	On-premise (system with specialized hardware)
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

cmAngio®

Tool A (cmAngiou00ae) emphasizes 'quick and easy installation (less than an hour)' and compatibility with 'any DICOM-compliant viewer', suggesting seamless integration into existing radiology workflows. Tool B (CARTOu2122 3 EP) is a complex surgical navigation system, inherently requiring more specialized setup and operation, despite its workflow streamlining features.

Clinical Value

CARTO 3 EP Navigation System Software V8.0 (FG-5400-00

Tool B (CARTOu2122 3 EP) offers direct, real-time enhancement of diagnosis and treatment for critical heart rhythm disorders during interventional procedures, potentially leading to immediate and profound patient outcomes. While Tool A (cmAngiou00ae) provides valuable opportunistic cardiovascular risk assessment from existing mammograms, Tool B's impact is on life-threatening conditions during active treatment.

Pricing & Value

Tie

Both tools lack public pricing transparency, requiring direct contact with the vendor for details. Although Tool A mentions 'limited-time offers for no-cost implementation and service,' this is not a standard pricing model, making a direct comparison of value propositions impossible without specific financial information for both.

Enterprise Readiness

CARTO 3 EP Navigation System Software V8.0 (FG-5400-00

Both tools are FDA-cleared and HIPAA-compliant. However, Tool B (CARTOu2122 3 EP) explicitly states that a Business Associate Agreement (BAA) is available for its associated cloud platform (CARTONETu2122), providing clearer enterprise-level compliance assurance. Its hybrid on-premise and optional cloud deployment also offers greater flexibility for diverse IT infrastructures.

Innovation

CARTO 3 EP Navigation System Software V8.0 (FG-5400-00

While Tool A (cmAngiou00ae) innovatively extracts new cardiovascular risk insights from existing mammograms, Tool B (CARTOu2122 3 EP) integrates advanced AI/machine learning into real-time 3D cardiac mapping and navigation for complex electrophysiology procedures. This application of AI in live interventional settings for enhanced signal analysis and automated anatomical mapping represents a more significant technological leap.

Support & Docs

Tie

Neither the provided structured facts nor general web searches offer sufficient specific detail regarding the depth, accessibility, or quality of support and documentation for either tool. Both companies appear to offer standard customer support and training resources, but a definitive comparison is not possible.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	cmAngio®	CARTO 3 EP Navigation System Software V8.0 (FG-5400-00
Product Name	cmAngiou00ae	CARTOu2122 3 EP Navigation System Software V8.0 (FG-5400-00
Company	CureMetrix	Biosense Webster, Inc.
Primary Function	FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment.	FDA-cleared, AI-powered 3D cardiac mapping and navigation system for electrophysiologists, enhancing diagnosis and treatment of heart rhythm disorders like AFib and VT.
Categories	Cardiology AI, OB/GYN AI, Radiology & Imaging AI	Cardiology AI, Surgical AI
Specialties	Cardiology, Obstetrics & Gynecology, Radiology	Cardiology
Key AI Application Focus	AI-based detection of Breast Arterial Calcifications (BAC)	AI-powered 3D cardiac mapping and navigation; machine learning for enhanced signal analysis; AI/deep-learning for automated 3D left atrial anatomy creation.